Ronald Nahass
Rutgers, The State University of New Jersey(US)Hillsborough Hospital(CA)Johnson University(US)
Publications by Year
Research Areas
Hepatitis C virus research, Hepatitis B Virus Studies, Liver Disease Diagnosis and Treatment, HIV/AIDS drug development and treatment, COVID-19 Clinical Research Studies
Most-Cited Works
- → Remdesivir for 5 or 10 Days in Patients with Severe Covid-19(2020)1,431 cited
- → Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection(2014)1,302 cited
- → Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection(2018)721 cited
- → Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy(2016)362 cited
- → Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial(2014)279 cited
- → Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection